Aligos Therapeutics Reports 40% Of HBeAg+ Chronic HBV Patients Achieve HBsAg Reduction After 48 Weeks Of Pevifoscorvir Sodium

Benzinga Newsdesk www.benzinga.com Positive 73.1%